“We do not expect a material impact to our robust outlook in psoriasis from any existing or new therapies this year and beyond.”

How to check this claim

Look at: Company-reported psoriasis franchise revenue (e.g., Skyrizi psoriasis indication sales/growth as disclosed)

It came true if: Psoriasis-related revenue growth remains positive year-over-year in FY2026, without material deceleration attributed by management to competitive therapies

Where: ABBV quarterly earnings releases and 10-K/10-Q segment/product revenue disclosures, plus management commentary on earnings calls

Verify independently

SEC filings for ABBV ↗ · Claim quote is verbatim from the 2025Q4 earnings call.